Science & Enterprise subscription

Follow us on Twitter

  • A chart posted on Friday by Statista provides yet another sign our planet is getting dangerously warmer.…
    about 5 hours ago
  • New post on Science and Enterprise: Infographic – More Data Show a Warming Planet #Science #Business
    about 5 hours ago
  • Capt. ‘Sully’ Sullenberger: Like Joe Biden, I Once Stuttered, Too. I Dare You to Mock Me.
    about 8 hours ago
  • New data show most sponsors of clinical trials are not reporting their results on time to a U.S. government web sit…
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Mediocre Report Rates #Science #Business
    about 1 day ago

Please share Science & Enterprise

PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies

AIDS ribbon (


A report by Pharmaceutical Research and Manufacturers of America (PhRMA) says U.S. biopharmaceutical companies are testing 88 medicines and vaccines to treat or prevent HIV/AIDS and related conditions. The report, issued on World AIDS Day (1 December 2011), also lists 36 currently approved medications for HIV infection and AIDS.

According to PhRMA’s report, more than half (49 of 88 or 56%) of the medications in development are antivirals, with another 27 drugs classified as vaccines. The remaining 12 medicines are cell or gene therapies, immunomodulators, and others treating related disorders (e.g. AIDS-associated neuropathy). All of the 88 drugs listed are either in clinical trials or awaiting FDA review.

In a statement, the International AIDS Vaccine Initiative (IAVI) says the global rate of new infections has stabilized at 2.7 million new infections a year for the past five years. IAVI attributes this stabilization to HIV control strategies including condoms, male circumcision, prevention of mother-to-child HIV transmission, harm reduction for people who use drugs, and a decrease in transmission from people living with HIV who are on treatment.

The group notes that antiretroviral treatments have been available since 1996, and are now more tolerable and a lot easier to take, although less than half of the people who need these treatments have access to them. “Fortunately,” says IAVI, “there have been extraordinary advances in HIV science, including significant progress toward the development of preventive vaccines and microbicides, the use of antiretroviral treatments as prophylaxis, and even a functional cure.”

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to PhRMA: 88 HIV/AIDS Meds in Development at U.S. Companies